The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …

Atypical antipsychotics (AAPs) are commonly prescribed medications to treat schizophrenia,
bipolar disorders and other psychotic disorders. However, they might cause metabolic …

The glucagon-like peptide (GLP)-1 receptor (GLP-1R) is a class BG protein–coupled
receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three …

The increasing prevalence, variable pathogenesis, progressive natural history, and
complications of type 2 diabetes emphasise the urgent need for new treatment strategies …

Class B G-protein-coupled receptors are major targets for the treatment of chronic diseases,
including diabetes and obesity. Structures of active receptors reveal peptide agonists …

The glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR) are
members of the secretin-like class B family of G-protein-coupled receptors (GPCRs) and …

Abstract Glucagon-like peptide-1 (7–36) amide (GLP-1) is a secreted peptide that acts as a
key determinant of blood glucose homeostasis by virtue of its abilities to slow gastric …

The global obesity epidemic has resulted in significant morbidity and mortality. However, the
medical treatment of obesity is limited. Gastric bypass is an effective surgical treatment but …

Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized
diabetes therapy, but their use has been limited because they require injection. Herein, we …

Glucagon‐like peptide‐1 (7‐36) amide (GLP‐1) is a 30‐residue peptide hormone released
from intestinal L cells following nutrient consumption. It potentiates the glucose‐induced …